Medtronic stock is down on new RDN system setback

Medtronic stock is taking a hit a day after an FDA review panel found the risks of its renal denervation system outweighed the benefits. 

Related Keywords

Palo Alto ,California ,United States ,Ryan Zimmerman ,Mike Matson ,Richard Lange ,Symplicity Spyral ,Sam Durno ,Jason Weidman ,Massdevice Medtech ,Jim Hammerand ,Iseult Mcmahon ,Circulatory Systems Devices Panel ,European Union ,Devices Advisory Committee ,Medtronic ,Managing Editor Jim Hammerand ,Medical Design ,Renal Denervation ,Cor Medical ,Recor Medical ,Otsuka Medical Devices ,David Rescott ,